Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1987-10-28
1989-08-29
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3142
Patent
active
048617903
ABSTRACT:
The invention involves a method for treating or preventing a malignant hyperthermic reaction in a human or lower animal by administering a safe and effective amount of azumolene.
REFERENCES:
patent: 3415821 (1968-12-01), Davis et al.
patent: 4049650 (1977-09-01), White, Jr.
patent: 4543359 (1985-09-01), Ellis et al.
Felice-Johnson, J., T. Sudds, G. Bennett, "Malignant Hyperthermia: Current Perspectives", American Journal of Hospital Pharmacy, vol. 38, No. 5, (May, 1981) pp. 646-651.
Physicians' Desk Reference, 42nd Ed., p. 1475 (1988).
Physicians' Desk Reference, 42nd Ed., p. 1476 (1988).
Ellis Keith O.
White, Jr. Ralph L.
Goldberg Jerome D.
Graff IV Milton B.
Norwich Eaton Pharmaceuticals, Inc.
Schaeffer Jack D.
Suter David L.
LandOfFree
Use of azumolene for the treatment of malignant hyperthermia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of azumolene for the treatment of malignant hyperthermia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of azumolene for the treatment of malignant hyperthermia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2238569